Multi-serotype outer membrane vesicles of Shigellae confer passive protection to the neonatal mice against shigellosis

Vaccine

Volumn 31, Issue 31, 2013, Pages 3163-3173

  Mitra, Soma ^a   Chakrabarti, Manoj K ^a   Koley, Hemanta ^a  

^a NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

Author keywords

Immunoglobulin; Mice model; Multi serotype; Oral immunization; Outer membrane vesicle; Shigella sp.; Vaccine

Indexed keywords

SHIGELLA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL OUTER MEMBRANE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNOLOGICAL PARAMETERS; MOUSE; NEWBORN; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SEROTYPE; SHIGELLA; SHIGELLA BOYDII; SHIGELLA DYSENTERIAE; SHIGELLA FLEXNERI; SHIGELLOSIS; WILD TYPE;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; BACTERIAL OUTER MEMBRANE PROTEINS; CELL MEMBRANE; DYSENTERY, BACILLARY; FEMALE; GASTROINTESTINAL CONTENTS; IMMUNITY, CELLULAR; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNOGLOBULINS; INTERLEUKIN-8; MACROPHAGES; MICE; PHAGOCYTOSIS; SHIGELLA DYSENTERIAE; SHIGELLA FLEXNERI; SHIGELLA SONNEI; SHIGELLA VACCINES;

EID: 84879111106     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.05.001     Document Type: Article

References (50)

1. Kotloff K.L., Winickoff J.P., Ivanoff B., Clemens J.D., Swerdlow D.L., Sansonetti P.J., et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999, 77:651-666.
2. Levine M.M., Kotloff K.L., Barry E.M., Pasetti M.F., Sztein M.B. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol 2007, 5:540-553.
3. Pasetti M.F., Simon J.K., Sztein M.B., Levine M.M. Immunology of gut mucosal vaccines. Immunol Rev 2011, 239:125-148.
4. von Seidlein L., Kim D.R., Ali M., Lee H., Wang X., Thiem V.D., et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med 2006, 3:e353.
5. Phalipon A., Sansonetti P.J. Shigellosis: innate mechanisms of inflammatory destruction of the intestinal epithelium, adaptive immune response, and vaccine development. Crit Rev Immunol 2003, 23:371-401.
6. Girard M.P., Steele D., Chaignat C.L., Kieny M.P. A review of vaccine research and development: human enteric infections. Vaccine 2006, 24:2732-2750.
7. Levine M.M. Enteric infections and the vaccines to counter them: future directions. Vaccine 2006, 24:3865-3873.
8. Datta S.K., Okamoto S., Hayashi T., Shin S.S., Mihajlov I., Fermin A., et al. Vaccination with irradiated Listeria induces protective T cell immunity. Immunity 2006, 25:143-152.
9. Kaminski R.W., Oaks E.V. Inactivated and subunit vaccines to prevent shigellosis. Expert Rev Vaccines 2009, 8:1693-1704.
10. Alaniz R.C., Deatherage B.L., Lara J.C., Cookson B.T. Membrane vesicles are immunogenic facsimiles of Salmonella typhimurium that potently activate dendritic cells, prime B and T cell responses, and stimulate protective immunity in vivo. J Immunol 2007, 179:7692-7701.
11. Schild S., Nelson E.J., Camilli A. Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice. Infect Immun 2008, 76:4554-4563.
12. Schild S., Nelson E.J., Bishop A.L., Camilli A. Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera. Infect Immun 2009, 77:472-484.
13. Roy N., Barman S., Ghosh A., Pal A., Chakraborty K., Das S.S., et al. Immunogenicity and protective efficacy of Vibrio cholerae outer membrane vesicles in rabbit model. FEMS Immunol Med Microbiol 2010, 60:18-27.
14. Granoff D.M. Review of meningococcal group B vaccines. Clin Infect Dis 2010, 2:S54-S65.
15. Rosenqvist E., Høiby E.A., Bjune G., Aase A., Halstensen A., Lehmann A.K., et al. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine. Dev Biol Stand 1998, 92:323-333.
16. Dalseg R., Wedege E., Holst J., Haugen I.L., Høiby E.A., Haneberg B. Outer membrane vesicles from group B meningococci are strongly immunogenic when given intranasally to mice. Vaccine 1999, 17:2336-2345.
17. Haneberg B., Dalseg R., Wedege E., Høiby E.A., Haugen I.L., Oftung F., et al. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect Immun 1998, 66:1334-1341.
18. Kesavalu L., Ebersole J.L., Machen R.L., Holt S.C. Porphyromonas gingivalis virulence in mice: induction of immunity to bacterial components. Infect Immun 1992, 60:1455-1464.
19. Keenan J., Day T., Neal S., Cook B., Perez-Perez G., Allardyce R., et al. A role for the bacterial outer membrane in the pathogenesis of Helicobacter pylori infection. FEMS Microbiol Lett 2000, 182:259-264.
20. Camacho A.I., de Souza J., Sánchez-Gómez S., Pardo-Ros M., Irache J.M., Gamazo C. Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice. Vaccine 2011, 29:8222-8229.
21. Mitra S., Barman S., Nag D., Sinha R., Saha D.R., Koley H. Outer membrane vesicles of Shigella boydii type 4 induce passive immunity in neonatal mice. FEMS Immunol Med Microbiol 2012, (July (4)). 10.1111/j.1574-695X.2012.01004.x.
22. Noriega F.R., Liao F.M., Maneval D.R., Ren S., Formal S.B., Levine M.M. Strategy for cross-protection among Shigella flexneri serotypes. Infect Immun 1999, 67:782-788.
23. Nandy S., Mitra U., Rajendran K., Dutta P., Dutta S. Subtype prevalence, plasmid profiles and growing fluoroquinolone resistance in Shigella from Kolkata, India (2001-2007): a hospital-based study. Trop Med Int Health 2010, 15:1499-1507.
24. Barman S., Kumar R., Chowdhury G., Rani Saha D., Wajima T., Hamabata T., et al. Live non-invasive Shigella dysenteriae 1 strain induces homologous protective immunity in a guinea pig colitis model. Microbiol Immunol 2011, 55:683-693. 10.1111/j.1348-0421.2011.00371.
25. Dutta S., Iida K., Takade A., Meno Y., Nair G.B., Yoshida S. Release of Shiga toxin by membrane vesicles in Shigella dysenteriae serotype 1 strains and in vitro effects of antimicrobials on toxin production and release. Microbiol Immunol 2004, 48:965-969.
26. Sereny B. Experimental keratoconjunctivitis shigellosa. Acta Microbiol Acad Sci Hung 1957, 4:367.
27. Kim K.P., Loessner M.J. Enterobacter sakazakii invasion in human intestinal Caco 2 cells requires the host cell cytoskeleton and is enhanced by disruption of tight junction. Infect Immun 2008, 76:562-570.
28. Balsalobre C., Silvan J.M., Berglund S., Mizunoe Y., Uhlin B.E., Wai S.N. Release of the type I secreted alpha-haemolysin via outer membrane vesicles from Escherichia coli. Mol Microbiol 2006, 59:99-112.
29. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
30. Keren D.F. Enzyme-linked immunosorbent assay for immunoglobulin G and immunoglobulin A antibodies to Shigella flexneri antigens. Infect Immun 1979, 24:441-448.
31. Iankov I.D., Petrov D.P., Mladenov I.V., Haralambieva I.H., Kalev O.K., Balabanova M.S., et al. Protective efficacy of IgA monoclonal antibodies to O and H antigens in a mouse model of intranasal challenge with Salmonella enterica serotype enteritidis. Microbes Infect 2004, 6:901-910.
32. Slauch J.M., Mahan M.J., Michetti P., Neutra M.R., Mekalanos J.J. Acetylation (O-factor 5) affects the structural and immunological properties of Salmonella typhimurium lipopolysaccharide O antigen. Infect Immun 1995, 63:437-441.
33. Pore D., Mahata N., Pal A., Chakrabarti M.K. Outer membrane protein A (OmpA) of Shigella flexneri 2a, induces protective immune response in a mouse model. PLoS ONE 2011, 6:e22663.
34. Sasakawa C., Buysse J.M., Watanabe H. The large virulence plasmid of Shigella. Curr Top Microbiol Immunol 1992, 180:21-44.
35. Van de Verg L.L., Mallett C.P., Collins H.H., Larsen T., Hammack C., Hale T.L. Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection. Infect Immun 1995, 63:1947-1954.
36. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007, 25:5467-5484.
37. Qadri F., Chowdhury M.I., Faruque S.M., Salam M.A., Ahmed T., Begum Y.A., et al. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine 2007, 25:231-238.
38. Qureshi K., Molbak K., Sandstrom A., Kofoed P.E., Rodrigues A., Dias F., et al. Breast milk reduces the risk of illness in children of mothers with cholera: observations from an epidemic of cholera in Guinea-Bissau. Pediatr Infect Dis J 2006, 25:1163-1166.
39. Goldman A.S. The immune system of human milk: antimicrobial, antiinflammatory and immunomodulating properties. Pediatr Infect Dis J 1993, 12:664-671.
40. Morrow A.L., Rangel J.M. Human milk protection against infectious diarrhea: implications for prevention and clinical care. Semin Pediatr Infect Dis 2004, 15:221-228.
41. Ijaz M.K., Sabara M.I., Frenchick P.J., Babiuk L.A. Effect of different routes of immunization with bovine rotavirus on lactogenic antibody response in mice. Antiviral Res 1987, 8:283-297.
42. McLay J., Leonard E., Petersen S., Shapiro D., Greenspan N.S., Schreiber J.R. 3 Gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides II. Increased susceptibility to fatal pneumococcal sepsis due to absence of anti-polysaccharide IgG3 is corrected by induction of anti-polysaccharide IgG1. J Immunol 2002, 168:3437-3443.
43. Lefeber D.J., Benaissa-Trouw B., Vliegenthart J.F., Kamerling J.P., Jansen W.T., Kraaijeveld K., et al. Th1 directing adjuvants increase the immunogenicity of oligosaccharideprotein conjugatevaccines related to Streptococcus pneumoniae type 3. Infect Immun 2003, 71:6915-6920.
44. Kadurugamuwa J.L., Beveridge T.J. Delivery of the non-membrane-permeative antibiotic gentamicin into mammalian cells by using Shigella flexneri membrane vesicles. Antimicrob Agents Chemother 1998, 42:1476-1483.
45. Sasakawa C., Komatsu K., Tobe T., Suzuki T., Yoshikawa M. Eight genes in region 5 that form an operon are essential for invasion of epithelial cells by Shigella flexneri 2a. J Bacteriol 1993, 175:2324-2346.
46. Oaks E.V., Hale T.L., Formal S.B. Serum immune response to Shigella protein antigens in rhesus monkeys and humans infected with Shigella spp. Infect Immun 1986, 53:57-63.
47. West N.P., Sansonetti P., Mounier J., Exley R.M., Parsot C., et al. Optimization of virulence functions through glucosylation of Shigella LPS. Science 2005, 307:1313-1317.
48. Jung H.C., Eckmann L., Yang S.K., Panja A., Fierer J., Morzycka-Wroblewska E., et al. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest 1995, 95:55-65.
49. Perdomo J.J., Gounon P., Sansonetti P.J. Polymorphonuclear leukocyte transmigration promotes invasion of colonic epithelial monolayer by Shigella flexneri. J Clin Invest 1994, 93:633-643.
50. Sansonetti P.J., Arondel J., Huerre M., Harada A., Matsushima K. Interleukin-8 controls bacterial transepithelial translocation at the cost of epithelial destruction in experimental shigellosis. Infect Immun 1999, 67:1471-1480.